The use of thyroid hormone receptor β (THR-β) agonists has been demonstrated to be an effective treatment for dyslipidemia and NAFLD; reductions in thyroid hormone may exacerbate both conditions [37,38]. Here, THRB is linked to metabolic syndrome.